Cargando…

Management of PTLD After Hematopoietic Stem Cell Transplantation: Immunological Perspectives

Post-transplant lymphoproliferative disorders (PTLDs) are life-threatening complications of iatrogenic immune impairment after allogeneic hematopoietic stem cell transplantation (HSCT). In the pediatric setting, the majority of PTLDs are related to the Epstein–Barr virus (EBV) infection, and present...

Descripción completa

Detalles Bibliográficos
Autores principales:	Compagno, Francesca, Basso, Sabrina, Panigari, Arianna, Bagnarino, Jessica, Stoppini, Luca, Maiello, Alessandra, Mina, Tommaso, Zelini, Paola, Perotti, Cesare, Baldanti, Fausto, Zecca, Marco, Comoli, Patrizia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526064/ https://www.ncbi.nlm.nih.gov/pubmed/33042147 http://dx.doi.org/10.3389/fimmu.2020.567020

Ejemplares similares

Harnessing T Cells to Control Infections After Allogeneic Hematopoietic Stem Cell Transplantation
por: Basso, Sabrina, et al.
Publicado: (2020)

Persistent rhinovirus infection in pediatric hematopoietic stem cell transplant recipients with impaired cellular immunity
por: Piralla, Antonio, et al.
Publicado: (2015)

Patient Blood Management after Hematopoietic Stem Cell Transplantation in a Pediatric Setting: Starting Low and Going Lower
por: Del Fante, Claudia, et al.
Publicado: (2023)

Adoptive Transfer of JC Virus‐Specific T Lymphocytes for the Treatment of Progressive Multifocal Leukoencephalopathy
por: Berzero, Giulia, et al.
Publicado: (2021)

The impact of viral respiratory infections in the first year post-transplant period of pediatric hematopoietic stem cell transplant (HSCT) recipients
por: Piralla, Antonio, et al.
Publicado: (2016)

Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS‐CoV‐2 infection
por: Avanzini, Maria A., et al.
Publicado: (2021)

Long-lasting responses with chemotherapy followed by T-cell therapy in recurrent or metastatic EBV-related nasopharyngeal carcinoma
por: Secondino, Simona, et al.
Publicado: (2023)

Blinatumomab induces complete response in refractory PTLD after hematopoietic cell transplantation
por: Janardan, Sanyukta, et al.
Publicado: (2022)

αβT- and B-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation in children with myelodysplastic syndromes
por: Merli, Pietro, et al.
Publicado: (2022)

Immunological Aspects of Human Papilloma Virus-Related Cancers Always Says, “I Am like a Box of Complexity, You Never Know What You Are Gonna Get”
por: Soleymaninejadian, Ehsan, et al.
Publicado: (2022)

Clinical Trials of Cellular Therapies in Solid Tumors
por: Secondino, Simona, et al.
Publicado: (2023)

Post-Transplant Lymphoproliferative Disease (PTLD) after Allogeneic Hematopoietic Stem Cell Transplantation: Biology and Treatment Options
por: Clerico, Michele, et al.
Publicado: (2022)

A case of post renal transplant PTLD of lung
por: Sinha, Tanay, et al.
Publicado: (2023)

P1388: EFFECTIVENESS AND SAFETY OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH ALLOGENEIC EBV-SPECIFIC T-CELL IMMUNOTHERAPY (TABELECLEUCEL) UNDER AN EXPANDED ACCESS PROGRAM IN EUROPE
por: Choquet, Sylvain, et al.
Publicado: (2023)

Mycobacterium chimaera Identification Using MALDI-TOF MS Technology: A Practical Approach for the Clinical Microbiology Laboratories
por: Bagnarino, Jessica, et al.
Publicado: (2022)

PTLD Burkitt Lymphoma in a Patient with Remote Lymphomatoid Granulomatosis
por: Stravodimou, A., et al.
Publicado: (2012)

Both SARS-CoV-2 infection and vaccination in pregnancy elicited neutralizing antibodies in pregnant women and newborns
por: Cassaniti, Irene, et al.
Publicado: (2021)

Serum and breastmilk SARS-CoV-2 specific antibodies following BNT162b2 vaccine: prolonged protection from SARS-CoV-2 in newborns and older children
por: Ricciardi, Alessandra, et al.
Publicado: (2022)

Monitoring of Human Cytomegalovirus and Virus-Specific T-Cell Response in Young Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation
por: Lilleri, Daniele, et al.
Publicado: (2012)

Differential outcome of neurological HCMV infection in two hematopoietic stem cell transplant recipients
por: Colombo, Anna Amelia, et al.
Publicado: (2012)

Immunity to Polyomavirus BK Infection: Immune Monitoring to Regulate the Balance between Risk of BKV Nephropathy and Induction of Alloimmunity
por: Comoli, Patrizia, et al.
Publicado: (2013)

P1457: DEMOGRAPHICS AND TREATMENT OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH OFF-THE-SHELF EBV-SPECIFIC CTL (TABELECLEUCEL) UNDER AN ONGOING EXPANDED ACCESS PROGRAM IN EUROPE: FIRST ANALYSES
por: Choquet, S., et al.
Publicado: (2022)

PD‐L1 and PD1 expression in post‐transplantation lymphoproliferative disease (PTLD) of childhood and adolescence: An inter‐ and intra‐individual descriptive study covering the whole spectrum of PTLD categories
por: Schiefer, Ana‐Iris, et al.
Publicado: (2019)

Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients
por: Bishnoi, Rohit, et al.
Publicado: (2017)

POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD) IN RENAL TRANSPLANT PATIENTS WITH COVID-19
por: MAHONEY, IAN, et al.
Publicado: (2022)

Inflammatory and Immune Responses during SARS-CoV-2 Infection in Vaccinated and Non-Vaccinated Pregnant Women and Their Newborns
por: Zelini, Paola, et al.
Publicado: (2023)

Immunology of THymectomy And childhood CArdiac transplant (ITHACA): protocol for a UK-wide prospective observational cohort study to identify immunological risk factors of post-transplant lymphoproliferative disease (PTLD) in thymectomised children
por: Offor, Ugonna T, et al.
Publicado: (2023)

O01 Post-transplant lymphoproliferative disorder (PTLD) in a patient with rheumatoid arthritis
por: Kim, Sung-Hee, et al.
Publicado: (2021)

P1346: EVALUATION OF CURRENT NATIONAL PRACTICE IN THE PREVENTION OF PTLD POST PAEDIATRIC HSCT
por: Kissane, E., et al.
Publicado: (2022)

Successful CAR T Cell Therapy in a Heart and Kidney Transplant Recipient With Refractory PTLD
por: Oren, Daniel, et al.
Publicado: (2022)

HLA-E–restricted immune responses are crucial for the control of EBV infections and the prevention of PTLD
por: Vietzen, Hannes, et al.
Publicado: (2023)

P1339: CLINICAL OUTCOMES OF PATIENTS WITH EBV+ PTLD FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION WHO FAIL RITUXIMAB: A MULTINATIONAL, RETROSPECTIVE CHART REVIEW STUDY
por: Sanz-Caballer, J., et al.
Publicado: (2022)

Post-transplant Lymphoproliferative Disorder (PTLD) in the US Population: Demographics, Treatment Characteristics, and Survival Analysis
por: Ullah, Asad, et al.
Publicado: (2023)

Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial
por: Zimmermann, Heiner, et al.
Publicado: (2022)

The role of nutrition in children with cancer
por: Tripodi, Serena Ilaria, et al.
Publicado: (2022)

Matched-pair analysis: identification of factors with independent influence on the development of PTLD after kidney or liver transplantation
por: Rausch, Lisa, et al.
Publicado: (2016)

Lytic EBV infection investigated by detection of Soluble Epstein-Barr virus ZEBRA in the serum of patients with PTLD
por: Habib, Mohammed, et al.
Publicado: (2017)

Late Onset Graft Plasmacytoma-Like PTLD Presenting as Acute Hyperglycemia in a Kidney-Pancreas Transplant Recipient
por: Ventura-Aguiar, P., et al.
Publicado: (2019)

Relationship between rabbit anti-thymocyte globulin and development of PTLD and its aggressive form in renal transplant population
por: Ali, Hatem, et al.
Publicado: (2020)

Sterile necrotizing and non-necrotizing granulomas in a heart transplant patient with history of PTLD: A unique finding
por: Piening, Nicholas, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_v996bq0i3uvv7mivguo6igjtn0